Journal article
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
Abstract
BACKGROUND: Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. This study investigated the efficacy and safety of bimekizumab in patients with moderate to severe plaque psoriasis, the effects of treatment withdrawal, and two maintenance dosing schedules over 56 weeks.
METHODS: BE READY was a phase 3, multicentre, randomised, double-blind, placebo-controlled trial done at 77 sites …
Authors
Gordon KB; Foley P; Krueger JG; Pinter A; Reich K; Vender R; Vanvoorden V; Madden C; White K; Cioffi C
Journal
The Lancet, Vol. 397, No. 10273, pp. 475–486
Publisher
Elsevier
Publication Date
February 2021
DOI
10.1016/s0140-6736(21)00126-4
ISSN
0140-6736